Summit Securities Group’s Sonnet BioTherapeutics SONN Stock Holding History

Summit Securities Group’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$4.58K	–	1236
2025 Q3	$4.58K	Buy	+1,000	New	+$4.43K	﹤0.01%	927

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Summit Securities Group's SONN Position: Q4 2025 in Review

Summit Securities Group sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 1,000 shares — an estimated $4.58K sold.

Summit Securities Group first reported a position in SONN in Q3 2025 and held it in 1 quarter. The position peaked at $4.58K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

Summit Securities Group reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Summit Securities Group sold 1,000 Sonnet BioTherapeutics shares in Q4 2025, an estimated $4.58K.
Summit Securities Group first reported a position in Sonnet BioTherapeutics in Q3 2025 and held it in 1 quarter.
Summit Securities Group's Sonnet BioTherapeutics position peaked at $4.58K in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Summit Securities Group's 13F filing for Q4 2025, filed 17 Feb 2026.